Teva Pharmaceutical Industries (NYSE:TEVA) had its price objective upped by investment analysts at Piper Jaffray Companies from $6.00 to $7.00 in a research report issued to clients and investors on Friday, Stock Target Advisor reports. The brokerage currently has a “neutral” rating on the stock. Piper Jaffray Companies’ target price indicates a potential downside of 24.73% from the stock’s previous close.
A number of other analysts also recently issued reports on the stock. BMO Capital Markets dropped their target price on shares of Teva Pharmaceutical Industries from $11.00 to $9.00 and set a “market perform” rating for the company in a research report on Friday, August 9th. Wolfe Research began coverage on shares of Teva Pharmaceutical Industries in a research report on Friday, July 19th. They issued a “peer perform” rating and a $9.00 price objective for the company. UBS Group set a $8.00 price objective on shares of Teva Pharmaceutical Industries and gave the company a “hold” rating in a research report on Friday, August 16th. Morgan Stanley downgraded shares of Teva Pharmaceutical Industries from an “equal weight” rating to an “underweight” rating and lowered their price objective for the company from $16.00 to $6.00 in a research report on Monday, July 15th. Finally, Gabelli raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research report on Wednesday, October 16th. Six equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of “Hold” and an average price target of $10.78.
NYSE TEVA opened at $9.30 on Friday. Teva Pharmaceutical Industries has a 12 month low of $6.07 and a 12 month high of $23.97. The company has a 50-day moving average of $7.51 and a 200-day moving average of $8.90. The company has a debt-to-equity ratio of 1.73, a current ratio of 0.96 and a quick ratio of 0.62. The company has a market cap of $9.32 billion, a P/E ratio of 3.32, a P/E/G ratio of 0.89 and a beta of 1.73.
Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Wednesday, August 7th. The company reported $0.57 EPS for the quarter, beating the Zacks’ consensus estimate of $0.55 by $0.02. The company had revenue of $4.34 billion during the quarter, compared to the consensus estimate of $4.25 billion. Teva Pharmaceutical Industries had a negative net margin of 21.94% and a positive return on equity of 16.04%. The company’s quarterly revenue was down 7.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.78 EPS. As a group, equities research analysts anticipate that Teva Pharmaceutical Industries will post 2.26 EPS for the current year.
Several institutional investors have recently added to or reduced their stakes in TEVA. First Interstate Bank acquired a new position in Teva Pharmaceutical Industries during the second quarter worth $28,000. Pacer Advisors Inc. bought a new position in Teva Pharmaceutical Industries in the 2nd quarter worth approximately $32,000. AdvisorNet Financial Inc raised its position in Teva Pharmaceutical Industries by 71.3% in the 3rd quarter. AdvisorNet Financial Inc now owns 3,665 shares of the company’s stock worth $25,000 after purchasing an additional 1,525 shares during the last quarter. Kavar Capital Partners LLC bought a new position in Teva Pharmaceutical Industries in the 2nd quarter worth approximately $35,000. Finally, Motco bought a new position in Teva Pharmaceutical Industries in the 3rd quarter worth approximately $28,000. Institutional investors own 58.21% of the company’s stock.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Recommended Story: Cash Asset Ratio
Receive News & Ratings for Teva Pharmaceutical Industries Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com’s FREE daily email newsletter.
